• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Research and Markets: Examine the Performance, Products, Pipeline and Potential of Merck & Co

Posted on: Friday, 28 September 2007, 09:00 CDT

Research and Markets (http://www.researchandmarkets.com/reports/c69938) has announced the addition of "Merck & Co: Performance, Products, Pipeline and Potential" to their offering.

Pharmaceutical company intelligence reports from provide a full review of the company's activities together with five-year sales forecasts for its key products. The company's financial performance is covered in-depth, from its latest results to a complete analysis of its latest full fiscal year and an outlook for the future. A section on company strategy covers mergers, acquisitions and divestitures, key agreements, products and R&D.

An overview of key products and R&D is followed by a comprehensive review of the company's product portfolio and research and development pipeline by therapeutic area. In addition, supplementary appendices provide more in-depth information on financials, agreements and corporate events.

Established in 1891, Merck & Co discovers, develops, manufactures and markets vaccines and pharmaceutical medicines to address unmet medical needs. The company operates on a global basis and is represented in more than 200 countries. Merck's headquarters are based in Whitehouse Station, NJ.

In December 2005, Merck announced a new research and development model designed to increase productivity and improve the probability of success by prioritising the company's R&D resources on nine priority disease areas: Alzheimer's disease, atherosclerosis, cardiovascular disease, diabetes, novel vaccines, obesity, oncology, pain and sleep disorders. Within these therapeutic areas, Merck will commit resources to achieve research breadth and depth, and to develop best-in-class targeted and differentiated products.

Merck will also make focused investments to pursue specific mechanisms in the following selected disease areas: antibiotics, antifungals, antivirals (hepatitis C and HIV), asthma, chronic obstructive pulmonary disease, neurodegeneration, ophthalmology, osteoporosis, schizophrenia and stroke. In addition, the company will capitalise on selected opportunities outside these areas, by continuing to commercialise attractive clinical development candidates in the pipeline and by pursuing appropriate external licensing opportunities.

Merck plans to place more emphasis on active engagement with key opinion leaders to accelerate the development and diffusion of scientific information and devote additional resources to utilising technology and demonstrating product value to physicians. In the US, this approach has already resulted in productivity improvements in pilot programmes and is expected to lower Merck's spending per brand by 15 to 20 per cent by 2010.

In order to rejuvenate the company profile following the withdrawal of Vioxx, Merck has developed an impressive pipeline dominated by novel candidate compounds. Merck is also looking to expand therapeutic areas where it has experienced strong and recent success.

For more information, visit http://www.researchandmarkets.com/reports/c69938

Source: Espicom

Source: Business Wire

More News in this Category